Drugs / Cerebrolysin
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06489925 | Jul 2024 → May 2025 overdue | basilar artery occlusion, brain infarction | University Hospital Sestre Milosrdnice | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06339411 | May 2024 → Dec 2026 expected | ischemic stroke | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02149875 | Jan → May 2010 | cerebral artery occlusion | Shanghai 6th People's Hospital | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05755997 | Nov 2023 → Mar 2026 overdue | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 | Ever Neuro Pharma GmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02116348 | Apr 2014 → Apr 2016 | cerebral palsy, developmental delay with or without epilepsy, intellectual disability, traumatic brain injury | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT01059461 | Mar 2011 → Sep 2013 | brain hypoxia - ischemia | Sahar M.A. Hassanein, MD | Completed | No outcome recorded |
| Phase 2 | NCT00911807 | Oct 2004 → Apr 2008 | Alzheimer disease | Ever Neuro Pharma GmbH | Completed | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT06052787 | Sep 2023 → May 2025 | traumatic brain injury | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04904341 | Jan 2021 → Dec 2023 | ischemic stroke | Military Institute od Medicine National Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT04830943 | Aug 2020 → Sep 2021 | anosmia | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT00840671 | Oct 2005 → Mar 2008 | stroke disorder | Ever Neuro Pharma GmbH | Completed | Missed primary |
| Phase 412 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT06899464 | Oct 2025 → Jan 2027 expected | intracerebral hemorrhage | Cardinal Stefan Wyszynski University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04427241 | Jun 2023 → Sep 2026 overdue | hemorrhagic stroke | Konkuk University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06078215 | Jan 2023 → Jan 2025 | ischemic stroke | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT06273020 | Nov 2022 → Nov 2024 | ischemic stroke, type 2 diabetes mellitus | Hospital Universitario Dr. Jose E. Gonzalez | Unknown | No outcome recorded |
| Phase 4 | NCT04913831 | Jun 2021 → Mar 2024 | stroke disorder | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT02768571 | Mar 2016 → Feb 2019 | stroke disorder | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02581371 | Feb 2015 → Feb 2017 | ischemic stroke | Clinical Institute of the Brain, Russia | Unknown | No outcome recorded |
| Phase 4 | NCT01606111 | Sep 2013 → Jul 2015 | traumatic brain injury | Ever Neuro Pharma GmbH | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT01996761 | Jan 2011 → Jan 2014 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00947531 | Oct 2006 → Aug 2007 | vascular dementia | Ever Neuro Pharma GmbH | Completed | Met primary |
| Phase 4 | NCT00868283 | Sep 2006 → Oct 2010 | ischemic stroke | Ever Neuro Pharma GmbH | Completed | Missed primary |
| Phase 4 | NCT01822951 | ? → Sep 2016 | Alzheimer disease | Ever Neuro Pharma GmbH | Withdrawn | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07846488 | Dec 2026 → Jun 2028 expected | hemiplegia, ischemic stroke | National Hospital of Acupuncture, Vietnam | Not yet recruiting | No outcome recorded |
| — | NCT07043686 | Jun 2025 → Jul 2027 expected | ischemic stroke | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT06677502 | Jan 2024 → Jun 2025 overdue | cognitive disorder | Medical University of Lublin | Enrolling by invitation | No outcome recorded |
| — | NCT06070753 | Oct 2023 → Jun 2024 | ischemic stroke | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 1 | NCT03506841 Comparator | Jun 2016 → Jun 2019 | cerebral palsy | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT05821075 Comparator | Aug 2023 → Jan 2026 overdue | Bell's palsy | October 6 University | Recruiting | No outcome recorded |
| Phase 2 | NCT04124367 Comparator | Jun 2021 → Mar 2022 | stroke disorder | Ever Neuro Pharma GmbH | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04751136 Comparator | Sep 2016 → Feb 2019 | Down syndrome | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05124353 Comparator | Apr 2021 → Apr 2023 | ischemic stroke | Pomeranian Medical University Szczecin | Unknown | No outcome recorded |
| Phase 2/3 | NCT01787123 Comparator | Dec 2013 → Jan 2019 | brain aneurysm, brain ischemia, subarachnoid hemorrhage | Kwong Wah Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01388738 Comparator | Jan → Oct 2011 | stroke disorder | Clinical Institute of the Brain, Russia | Completed | No outcome recorded |
| Phase 4 | NCT06208540 Comparator | Aug 2021 → Apr 2024 | post-COVID-19 disorder | Sherifa Ahmed Hamed | Completed | No outcome recorded |
| — | NCT05864677 Comparator | Jan 2023 → Jun 2024 | brain injury, cognitive disorder, heart disorder | Medical University of Lublin | Unknown | No outcome recorded |
| — | NCT05288465 Background | Jun 2014 → Dec 2015 | hair anomaly | Autonomous University of Nuevo León | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cerebrolysin | “Drug: cerebrolysin” NCT04751136 ↗ |
| Known as | CBL | “The incidence of vascular dementia (VaD) has rapidly increased over the past few decades. Although officially approved medications for VaD remain limited, cerebrolysin (CBL)...” PMID 28458021 ↗ Apr 2017 |
| Known as | CBN | “Cerebrolysin (CBN) is a mixture of several neurotrophic factors and active peptides with anti-inflammatory, antioxidant, and neuroprotective actions.” PMID 34674598 ↗ Oct 2021 |
| Modality | Peptide | “Cerebrolysin is a parenterally administered neuropeptide preparation approved for treatment of stroke.” PMID 29248999 ↗ Dec 2017 |
| Route | Intravenous | “Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.” NCT00840671 ↗ |